Trade Names:Chorionic Gonadotropin- Powder for injection 5,000 units/vial with 10 mL diluent (to make 500 units/mL)- Powder for injection 10,000 units/vial with 10 mL diluent (to make 1,000 units/mL)
Trade Names:Novarel- Powder for injection 10,000 units/vial with 10 mL diluent (to make 1,000 units/mL)
Trade Names:Pregnyl- Powder for injection 10,000 units/vial with 10 mL diluent (to make 1,000 units/mL)
Trade Names:Profasi- Powder for injection 5,000 units/vial with 10 mL diluent (to make 500 units/mL)- Powder for injection 10,000 units/vial with 10 mL diluent (to make 1,000 units/mL)
Stimulates production of gonadal steroid hormones by stimulating interstitial cells (Leydig cells) of the testis to produce androgens and corpus luteum of the ovary to produce progesterone.
A detectable rise in human chorionic gonadotropin (hCG) is seen in 2 h; peak levels are reached in 6 h and remain at this level for 36 h.
hCG levels begin to decline at 48 h and approach baseline at 72 h.
Prepubertal cryptorchidism not caused by anatomical obstruction; selected cases of hypogonadotropic hypogonadism (eg, hypogonadism secondary to pituitary deficiency) in men; induction of ovulation in anovulatory, infertile women in whom the cause of anovulation is secondary and not caused by primary ovarian failure and who have been appropriately pretreated with human menotropins.
Precocious puberty; prostatic carcinoma or other androgen-dependent neoplasm; prior allergic reaction to hCG.
IM (1) 4,000 units 3 times/wk for 3 wk, (2) 5,000 units every other day for 4 injections, (3) 15 injections of 500 to 1,000 units over a period of 6 wk, or (4) 500 units 3 times/wk for 4 to 6 wk (if not successful, another course is begun 1 mo later using 1,000 units/injection).Hypogonadotropic Hypogonadism in MenAdults Various authorities have advocated the following regimens
IM 500 to 1,000 units 3 times/wk for 3 wk, followed by same dose twice a week for 3 wk, or 4,000 units 3 times/wk for 6 to 9 mo, following which the dosage may be reduced to 2,000 units 3 times/wk for an additional 3 mo.
Store vials at controlled room temperature (59° to 86°F). Store reconstituted solution in refrigerator (36° to 46°F) and use within 30 or 60 days per manufacturer's recommendations.
None well documented.
Interference with radioimmunoassay for gonadotropins, particularly luteinizing hormone.
Headache; irritability; restlessness; depression; fatigue.
Precocious puberty; gynecomastia.
Pain at injection site.
Monitor women for signs of overstimulation of the ovary (eg, difficulty breathing, severe pelvic pain, nausea, vomiting, weight gain, stomach pain or bloating, diarrhea, infrequent urination) and report to health care provider immediately if noted.
Category C .
Safety and efficacy in children younger than 4 yr of age not established.
Because chorionic gonadotropin may cause fluid retention, use with caution in patients with cardiac or renal disease, epilepsy, migraine, or asthma.
Ensure that women have had a thorough gynecological and endocrinological evaluation before starting therapy. Ensure that men have had a thorough medical and endocrinological evaluation before starting therapy.
Use in conjunction with human menopausal gonadotropins only by health care provider experienced with infertility problems.
May induce precocious puberty in patients treated for cryptorchidism.
Copyright © 2009 Wolters Kluwer Health.